ProQR's Vision 2023

In January 2019 we launched our ‘ProQR Vision 2023’ strategy, laying out our plans to build ProQR out into a multi-product, platform company independently developing and commercializing therapies for patients that suffer from Inherited Retinal Diseases. By 2023, the company expects its pipeline to have at least two commercial products, and at least three late-stage and seven early-stage programs in development. In parallel, the company will continue to expand its RNA platform capabilities in other therapeutic areas, and plans to selectively partner programs in non-core therapeutic areas and non-rare diseases.

ProQR's Vision 2023 strategy for Inherited Retinal Diseases: 2 Approved Products, 3 Late Stage Programs, 7 Early Stage Programs

“The ‘ProQR Vision 2023’ strategy presents a clear path for ProQR to become a fully-integrated company that is independently developing and commercializing innovative RNA medicines for patients who suffer from IRDs. Given the high unmet need across many of the 300 IRDs known today, we believe this integrated approach will allow us to more efficiently turn our scientific innovation into multiple potentially life-changing medicines for patients,” said Daniel A. de Boer, Chief Executive Officer of ProQR. “With our experienced team, predictive translational models and capabilities in precision medicine, we are well-positioned to execute on this long-term strategy and advance the field of medicines for inherited blindness.”

Click here to read our press release.